Analysts have raised their price target for Mativ Holdings from $15.50 to $16.50. They cite adjustments in valuation metrics and expectations for future company performance as reasons for this change.
What's in the News
- Mativ Holdings completed the repurchase of 539,386 shares, representing 0.99% of outstanding shares, for $7.99 million under the buyback program announced on August 1, 2023 (Key Developments).
- No share repurchases occurred between July 1, 2025 and November 3, 2025. The total for this tranche remained at 0 shares and $0 million (Key Developments).
Valuation Changes
- Fair Value Estimate has increased from $15.50 to $16.50, reflecting a higher assessment of intrinsic value.
- Discount Rate has decreased from 10.84% to 10.40%, suggesting analysts see lower perceived risk or improved cost of capital.
- Revenue Growth projections declined moderately from 2.08% to 1.89%.
- Net Profit Margin is projected to fall sharply, moving from 9.45% previously to 1.57% in the updated assessment.
- Future P/E Ratio forecast has risen significantly, increasing from 5.87x to 37.20x. This indicates a higher valuation on expected future earnings.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.